NPC1

Phase 2Small molecule

MMassachusetts General Hospital

NPC1 is one of 13 small molecule programs targeting Biomarker. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BiomarkerNot yet recruiting

BiomarkerPhase 2

Not yet recruiting

Competition

Competitive Landscape

13 competitors in Biomarker

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

2 2

Nucala

GGlaxo Dba Glaxosmithkline

Approved

1 3

Ibrance

Pfizer

Phase 2

2 4

Acthar

MMallinckrodt

Phase 3

1 5

PD-1 Blocking Antibody

SSun Yat-sen University

Phase 2

1 6

Hyperpolarized Xenon-129

TThunder Bay Regional Health Research Institute

Phase 3

1 7

Aspercreme Warming

AAveritas Pharma, Inc.

Phase 1

1 8

Galunisertib

Eli Lilly

Phase 2

1 9

NPC1

MMassachusetts General Hospital

Phase 2

1 10

Somavert

PPharmacia and Upjohn

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Not yet recruiting

Biomarker

NCT07236190

Clinical

Trials by Indication[1]

Biomarker1 trial

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

Not yet recruiting·MMassachusetts General Hospital·Phase 1/2·NCT07236190·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NPC1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NPC1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NPC1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMassachusetts General Hospital

NPC1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Biomarker1 trial

References

Drug Info

Quick Facts

Related News